Kang Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kang Cai has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Etienne Utiger
Biopharmaceutical Development AstraZeneca Maryland USA
2 shared publications- Gisela Ferreira
Biopharmaceutical Development AstraZeneca Maryland USA
2 shared publications Jennifer Anderson
Biopharmaceutical Development AstraZeneca Maryland USA
2 shared publications- Peter M. Vallone
Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, USA
2 shared publications William G. Valiant
Biomolecular Measurement Division, Applied Genetics Group, National Institute of Standards and Technology, Gaithersburg, MD, USA
2 shared publicationsChris Afdahl
Biopharmaceutical Development AstraZeneca Maryland USA
1 shared publication
Latest Publications
- Open Access
- 6 May 2026
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 123 (7) , 1976-1984
Detergent Virus Inactivation in Chromatography Systems
Detergent treatment is a widely utilized virus‐inactivation step in therapeutic protein manufacturing to safeguard products. Traditionally, this operation is performed in an incubation vessel in batch mode. In this investigation, a methodology was developed to enable virus inactivation via a post‐load, detergent‐containing wash within a bind‐elute chromatography process. Application of the non‐ionic detergent Laureth 9 during the post‐load wash achieved more than 4 logs of retrovirus inactivation. Chromatography control experiments conducted without detergent resulted in negligible virus inactivation. Simultaneous measurements of virus infectivity and genome copies distinguished the contributions of detergent‐driven net virus inactivation from those of separation‐driven net virus removal. These results establish a robust and simplified alternative approach for virus inactivation in therapeutic protein manufacturing.
- 6 May 2026
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 123 (7) , 1976-1984
Open AccessDetergent Virus Inactivation in Chromatography Systems
Detergent treatment is a widely utilized virus‐inactivation step in therapeutic protein manufacturing to safeguard products. Traditionally, this operation is performed in an incubation vessel in batch mode. In this investigation, a methodology was developed to enable virus inactivation via a post‐load, detergent‐containing wash within a bind‐elute chromatography process. Application of the non‐ionic detergent Laureth 9 during the post‐load wash achieved more than 4 logs of retrovirus inactivation. Chromatography control experiments conducted without detergent resulted in negligible virus inactivation. Simultaneous measurements of virus infectivity and genome copies distinguished the contributions of detergent‐driven net virus inactivation from those of separation‐driven net virus removal. These results establish a robust and simplified alternative approach for virus inactivation in therapeutic protein manufacturing.
- Open Access
- 21 February 2024
- Published by Elsevier in Biologicals
- Vol. 85, 101751
Viral clearance capability of monoclonal antibody purification
- 21 February 2024
- Published by Elsevier in Biologicals
- Vol. 85, 101751
Open AccessViral clearance capability of monoclonal antibody purification
- Open Access
- 28 December 2023
- Published by Elsevier in Biologicals
- Vol. 85, 101741
Efficient extraction of adventitious virus nucleic acid using commercially available methods
- 28 December 2023
- Published by Elsevier in Biologicals
- Vol. 85, 101741
Open AccessEfficient extraction of adventitious virus nucleic acid using commercially available methods
- Open Access
- 5 November 2022
- Published by Elsevier in Biologicals
- Vol. 80, 6-17
A history of adventitious agent contamination and the current methods to detect and remove them from pharmaceutical products
- 5 November 2022
- Published by Elsevier in Biologicals
- Vol. 80, 6-17
Open AccessA history of adventitious agent contamination and the current methods to detect and remove them from pharmaceutical products
- 1 May 2014
- Published by Elsevier in Biologicals
- Vol. 42 (3) , 133-138
Characterization of Thrombate III®, a pasteurized and nanofiltered therapeutic human antithrombin concentrate
- 1 May 2014
- Published by Elsevier in Biologicals
- Vol. 42 (3) , 133-138
Characterization of Thrombate III®, a pasteurized and nanofiltered therapeutic human antithrombin concentrate